SCH 46642
Latest Information Update: 29 Mar 1996
Price :
$50 *
At a glance
- Originator Schering-Plough
- Class Antihypertensives; Bronchodilators; Heart failure therapies; Muscle relaxants
- Mechanism of Action Cyclic GMP phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 29 Mar 1996 No-Development-Reported for Heart failure in USA (Unknown route)
- 31 Jan 1995 New profile
- 31 Jan 1995 Preclinical development for Heart failure in USA (Unknown route)